We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...